Fig. 3.
Kaplan-Meier estimates of A) progression-free survival and B) overall survival in patients continuing versus ceasing bevacizumab treatment after disease progression
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.